Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

BACKGROUND: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Peter, Blennow, Ola, Hansson, Lotta, Mielke, Stephan, Nowak, Piotr, Chen, Puran, Söderdahl, Gunnar, Österborg, Anders, Smith, C. I. Edvard, Wullimann, David, Vesterbacka, Jan, Lindgren, Gustaf, Blixt, Lisa, Friman, Gustav, Wahren-Borgström, Emilie, Nordlander, Anna, Gomez, Angelica Cuapio, Akber, Mira, Valentini, Davide, Norlin, Anna-Carin, Thalme, Anders, Bogdanovic, Gordana, Muschiol, Sandra, Nilsson, Peter, Hober, Sophia, Loré, Karin, Chen, Margaret Sällberg, Buggert, Marcus, Ljunggren, Hans-Gustaf, Ljungman, Per, Aleman, Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629680/
https://www.ncbi.nlm.nih.gov/pubmed/34861491
http://dx.doi.org/10.1016/j.ebiom.2021.103705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629680/
https://www.ncbi.nlm.nih.gov/pubmed/34861491
http://dx.doi.org/10.1016/j.ebiom.2021.103705

Ejemplares similares